首页 | 本学科首页   官方微博 | 高级检索  
     


Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
Authors:Maria-Victoria Mateos  Robert Z. Orlowski  Enrique M. Ocio  Paula Rodríguez-Otero  Donna Reece  Philippe Moreau  Nikhil Munshi  David E. Avigan  David S. Siegel  Razi Ghori  Mohammed Z. H. Farooqui  Patricia Marinello  Jesus San-Miguel
Affiliation:1. Complejo Asistencial Universitario de Salamanca/IBSAL & Centro de Investigación del Cáncer (IBMCC-CSIC-USAL), Salamanca, Spain;2. The University of Texas MD Anderson Cancer Center, Houston, TX, USA;3. Hospital Universitario Marqués de Valdecilla (IDIVAL) & University of Cantabria, Santander, Spain;4. Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain;5. Princess Margaret Cancer Centre, Toronto, ON, Canada;6. University Hospital Hotel-Dieu, Nantes, France;7. Dana-Farber Cancer Institute, Boston, MA, USA;8. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA;9. John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA;10. Merck & Co, Inc, Kenilworth, NJ, USA
Abstract:
Keywords:pembrolizumab  relapsed/refractory  multiple myeloma  lenalidomide  dexamethasone
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号